tri agonist glp 1 LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Hitting the Triple G Spot:
Description
For now, we better focus on the so what?
That does not mean every result is proven for every patient
DHVR has acted as a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck, and Novo Nordisk and has received research funding from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, and Novo Nordisk
Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimers disease
2016b;375:1834
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes mellitus: friends or foes to bone health
